| Name | Arix Bioscience |
|---|---|
| Epic | ARIX |
| Isin | GB00BD045071 |
| Index | MID300 |
| Industry | Investment Banking and Brokerage Services |
| Latest share price | 142.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £183.73 | Debt ratio | n/a |
| Shares in issue | 129.39 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -12.9 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -23.9 | 52-week high / low | 97.00p / 144.50p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Arix Bioscience |
|---|---|
| Address | Duke Street House, 50 Duke Street, London, United Kingdom, W1K 6JL |
| Telephone | +44 (0)20 7290 1050 |
| Website | www.arixbioscience.com |
| Director | Position |
|---|---|
| Mr Robert Lyne | CEO |
| Hon Peregrine D E M Moncreiffe | Chairman |
| Mr Isaac Kohlberg | Non-Executive Director |
| Mr Andrew Smith | Non-Executive Director |
| Ms Maureen O'Connell | Non-Executive Director |
| Mrs Debra Barker | Senior Independent Director |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 0.02 | 0.17 | 0.31 |
| Investments and other non-current assets | 102.69 | 120.64 | 154.42 |
| Total non-current assets | 102.85 | 121.01 | 154.97 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | n/a | n/a | n/a |
| Cash and equivalents | 122.78 | 134.23 | 174.36 |
| Other current assets and asset held for resale | 2.22 | 1.84 | 1.38 |
| Total of all assets | 227.85 | 257.08 | 330.71 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 1.92 | 1.6 | 2.23 |
| Long term liabilities | 0.01 | 0.12 | 0.27 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 1.93 | 1.72 | 2.5 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 225.91 | 255.36 | 328.21 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 188.59 | 188.59 | 188.59 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | 51.25 | 80.69 | 142.04 |
| Share premium account | n/a | n/a | n/a |
| Total equity | 225.91 | 255.36 | 328.21 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -29.16 | -58.65 | 128.01 |
| Pre-tax profit | -27.58 | -61.08 | 126.3 |